The Evolution of Medications for Obesity Management.

A narrative review rather than a systematic one, so study selection reflects the authors' judgment and no pooled estimates are offered. Its value is as a readable synthesis of how the field moved past a history of market withdrawals to the current incretin class, with headline efficacy figures that align with the pivotal trials. Useful orientation; no new data.